PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.54M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
1.51%
Revenue growth under 50% of MCHP's 6.97%. Michael Burry would suspect a deteriorating sales pipeline or weaker brand.
2.75%
Gross profit growth under 50% of MCHP's 8.72%. Michael Burry would be concerned about a severe competitive disadvantage.
2.63%
EBIT growth below 50% of MCHP's 67.41%. Michael Burry would suspect deeper competitive or cost structure issues.
2.40%
Operating income growth under 50% of MCHP's 19.74%. Michael Burry would be concerned about deeper cost or sales issues.
2.95%
Net income growth under 50% of MCHP's 117.93%. Michael Burry would suspect the firm is falling well behind a key competitor.
3.03%
EPS growth under 50% of MCHP's 109.09%. Michael Burry would suspect deeper structural issues or share dilution limiting per-share gains.
3.96%
Diluted EPS growth under 50% of MCHP's 114.29%. Michael Burry would worry about an eroding competitive position or excessive dilution.
-0.11%
Share reduction while MCHP is at 0.94%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-0.21%
Reduced diluted shares while MCHP is at 0.37%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
0.20%
Dividend growth under 50% of MCHP's 5.11%. Michael Burry might suspect more pressing needs for cash or weaker earnings power.
-9.04%
Negative OCF growth while MCHP is at 40.23%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
58.23%
FCF growth above 1.5x MCHP's 38.04%. David Dodd would verify if the firm’s strategic investments yield superior returns.
94.62%
10Y revenue/share CAGR under 50% of MCHP's 191.02%. Michael Burry would suspect a lasting competitive disadvantage.
55.90%
5Y revenue/share CAGR similar to MCHP's 53.59%. Walter Schloss might see both companies benefiting from the same mid-term trends.
38.84%
3Y revenue/share CAGR above 1.5x MCHP's 11.21%. David Dodd would confirm if there's an emerging competitive moat driving recent gains.
491.32%
10Y OCF/share CAGR 1.25-1.5x MCHP's 425.12%. Bruce Berkowitz would confirm if the firm's long-term capital allocation yields better cash returns.
191.60%
5Y OCF/share CAGR above 1.5x MCHP's 120.03%. David Dodd would confirm if the firm has better cost structures or brand premium boosting mid-term cash flow.
97.03%
3Y OCF/share CAGR 1.25-1.5x MCHP's 78.97%. Bruce Berkowitz might see if strategic cost controls or product mix drove recent gains.
928.53%
Net income/share CAGR above 1.5x MCHP's 76.81% over 10 years. David Dodd would confirm if brand, IP, or scale secure this persistent advantage.
138.70%
5Y net income/share CAGR at 50-75% of MCHP's 274.46%. Martin Whitman might see a shortfall in operational efficiency or brand power.
83.99%
Below 50% of MCHP's 508.40%. Michael Burry suspects a steep short-term disadvantage in bottom-line expansion.
56.79%
10Y equity/share CAGR at 50-75% of MCHP's 103.99%. Martin Whitman would note a lag in capital accumulation vs. the competitor.
42.46%
5Y equity/share CAGR at 50-75% of MCHP's 70.52%. Martin Whitman would question a shortfall in capital accumulation vs. the competitor.
67.39%
Positive short-term equity growth while MCHP is negative. John Neff sees a strong advantage in near-term net worth buildup.
575.06%
10Y dividend/share CAGR above 1.5x MCHP's 19.19%. David Dodd checks if the firm's robust cash flows justify outpacing the competitor's increases.
129.88%
5Y dividend/share CAGR above 1.5x MCHP's 14.56%. David Dodd checks if the firm's mid-term cash flows justify a faster dividend growth rate.
49.37%
3Y dividend/share CAGR above 1.5x MCHP's 13.65%. David Dodd sees a superior short-term capital return strategy if supported by stable earnings.
5.53%
AR growth well above MCHP's 0.30%. Michael Burry fears inflated revenue or higher default risk in the near future.
7.85%
Inventory growth well above MCHP's 2.83%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
2.43%
Positive asset growth while MCHP is shrinking. John Neff sees potential for us to outgrow the competitor if returns are solid.
5.24%
BV/share growth above 1.5x MCHP's 2.46%. David Dodd confirms if consistent profit retention or fewer write-downs yield faster equity creation.
-5.65%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
0.51%
R&D dropping or stable vs. MCHP's 4.33%. David Dodd sees near-term margin benefits if the product pipeline is already strong.
4.46%
SG&A growth well above MCHP's 5.57%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.